MedPath

Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)

Phase 2
Completed
Conditions
Infertility
Interventions
Drug: Placebo
First Posted Date
2008-06-20
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
55
Registration Number
NCT00702585

Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)

Completed
Conditions
In Vitro Fertilization
Interventions
Biological: recFSH (follitropin alfa)
Drug: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Drug: human chorion gonadatropin (hCG)
Biological: progesterone
Drug: placebo-recFSH (follitropin alfa)
Drug: placebo-corifollitropin alfa
Biological: open-label recFSH
First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
102
Registration Number
NCT00702546

Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)

Phase 2
Completed
Conditions
In Vitro Fertilization
Infertility
Interventions
First Posted Date
2008-06-20
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
99
Registration Number
NCT00702806

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)

Completed
Conditions
Neonates
Pregnancy
Interventions
Drug: Corifollitropin alpha (MK-8962, Org 36286) 150 ug
Drug: Corifollitropin alpha (MK-8962, Org 36286) 100 ug
Biological: Recombinant follicle stimulating hormone (recFSH)
Biological: Human chorionic gonadotprophin (hCG).
First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
15
Registration Number
NCT00702520

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)

Completed
Conditions
Neonates
Pregnancy
Interventions
Biological: recFSH (follitropin beta)
Drug: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Biological: human chorion gonadotropin (hCG)
Biological: progesterone
Drug: placebo-recFSH (follitropin beta)
Drug: placebo-corifollitropin alfa
Biological: open-label recFSH (follitropin beta)
First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
113
Registration Number
NCT00702624

Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)

Completed
Conditions
Pregnancy
Neonates
Interventions
Drug: recFSH
First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
44
Registration Number
NCT00702988

A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: placebo (unspecified)
First Posted Date
2008-06-19
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
500
Registration Number
NCT00700661

A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

Phase 3
Completed
Conditions
In Vitro Fertilization
Interventions
Biological: RecFSH / Follitropin beta (Days 1 to 7)
Drug: Placebo RecFSH / follitropin beta
Drug: Placebo Corifollitropin alfa
Biological: RecFSH / Follitropin beta (Days 8 to hCG)
Biological: hCG
Biological: Progesterone
First Posted Date
2008-06-13
Last Posted Date
2024-06-20
Lead Sponsor
Organon and Co
Target Recruit Count
1509
Registration Number
NCT00696800

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

Phase 3
Completed
Conditions
In Vitro Fertilization
Interventions
Biological: FSH
Biological: GnRH antagonist
Biological: (rec)hCG
First Posted Date
2008-06-13
Last Posted Date
2024-06-18
Lead Sponsor
Organon and Co
Target Recruit Count
682
Registration Number
NCT00696878

A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)

Phase 2
Terminated
Conditions
Ovulation Induction
Interventions
Biological: human Chorion Gonadotropin (hCG)
Biological: recombinant Follicle Stimulating Hormone (recFSH)
Biological: hCG Bolus injection
First Posted Date
2008-06-13
Last Posted Date
2024-06-17
Lead Sponsor
Organon and Co
Target Recruit Count
8
Registration Number
NCT00697255
© Copyright 2025. All Rights Reserved by MedPath